Sheaff Brock Investment Advisors LLC Invests $169,000 in Anavex Life Sciences Corp. (NASDAQ:AVXL)

Sheaff Brock Investment Advisors LLC purchased a new position in Anavex Life Sciences Corp. (NASDAQ:AVXL) during the 4th quarter, Holdings Channel.com reports. The firm purchased 15,750 shares of the biotechnology company’s stock, valued at approximately $169,000.

Other hedge funds have also recently made changes to their positions in the company. JPMorgan Chase & Co. lifted its position in shares of Anavex Life Sciences by 2.9% during the third quarter. JPMorgan Chase & Co. now owns 42,565 shares of the biotechnology company’s stock valued at $242,000 after buying an additional 1,191 shares during the last quarter. China Universal Asset Management Co. Ltd. boosted its stake in Anavex Life Sciences by 10.2% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 17,980 shares of the biotechnology company’s stock worth $193,000 after purchasing an additional 1,671 shares during the last quarter. Foster Victor Wealth Advisors LLC boosted its position in shares of Anavex Life Sciences by 5.6% during the 4th quarter. Foster Victor Wealth Advisors LLC now owns 37,663 shares of the biotechnology company’s stock valued at $405,000 after acquiring an additional 2,000 shares during the last quarter. Carnegie Investment Counsel raised its holdings in Anavex Life Sciences by 4.7% in the 4th quarter. Carnegie Investment Counsel now owns 76,778 shares of the biotechnology company’s stock valued at $825,000 after buying an additional 3,445 shares during the period. Finally, Rhumbline Advisers increased its stake in Anavex Life Sciences by 2.9% during the fourth quarter. Rhumbline Advisers now owns 123,699 shares of the biotechnology company’s stock worth $1,329,000 after purchasing an additional 3,498 shares during the period. 31.55% of the stock is currently owned by institutional investors.

Anavex Life Sciences Stock Up 0.6 %

AVXL stock opened at $8.52 on Tuesday. The company has a market capitalization of $722.67 million, a PE ratio of -16.38 and a beta of 0.69. The stock’s 50 day moving average is $9.95 and its two-hundred day moving average is $7.74. Anavex Life Sciences Corp. has a 52-week low of $3.25 and a 52-week high of $14.44.

Anavex Life Sciences (NASDAQ:AVXL) last announced its quarterly earnings results on Wednesday, February 12th. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.03. As a group, sell-side analysts anticipate that Anavex Life Sciences Corp. will post -0.73 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on AVXL shares. D. Boral Capital reaffirmed a “buy” rating and issued a $46.00 price target on shares of Anavex Life Sciences in a report on Wednesday, February 12th. HC Wainwright restated a “buy” rating and issued a $42.00 price target on shares of Anavex Life Sciences in a research report on Tuesday, January 28th.

Anavex Life Sciences Profile

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.